Preventive or therapeutic agent for pain associated with herpes zoster in acute phase

Patent metadata

Field	Value
Publication number	US-9561235-B2
Application number	US-201514808609-A
Country	US
Kind code	B2
Filing date	Jul 24, 2015
Priority date	Nov 5, 2010
Publication date	Feb 7, 2017
Grant date	Feb 7, 2017

Abstract

A P2X 4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster-associated pain in acute phase:

wherein R 1 is hydrogen, a C 1-8 alkyl group, or the like;
each of R 2 and R 3 is hydrogen, a C 1-8 alkyl group, or the like; each of R 4 and R 5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

First claim

What is claimed is:

1. A method of treating prodrome or pain of herpes zoster in acute phase comprising administrating an effective amount of a compound having the following formula (VIII) or a pharmacologically acceptable salt thereof to a patient in need thereof:

wherein R 1 is hydrogen, a C 1-8 alkyl group, a C 2-8 alkenyl group, a C 1-8 alkyl group having one to three halogen atoms, or a C 1-3 alkyl group having phenyl;
R 2 is hydrogen, a C 1-8 alkyl group, a C 1-8 alkoxy group, a C 1-8 alkyl group having one to three halogen atoms, a C 1-8 alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, a C 1-8 alkylamino group, a C 2-8 dialkylamino group, a C 2-8 acylamino group, a C 2-8 acylamino group having one to three halogen atoms, a C 1-8 alkylsulfonylamino group, carboxyl, a C 2-8 acyl group, an alkoxycarbonyl group comprising a C 1-8 alkoxy moiety, carbamoyl, a C 1-8 alkylthio group, a C 1-8 alkylsulfinyl group, a C 1-8 alkylsulfonyl group, or sulfamoyl;
R 3 is hydrogen, a C 1-8 alkyl group, a C 1-8 alkoxy group, a C 1-8 alkyl group having one to three halogen atoms, a C 1-8 alkoxy group having one to three halogen atoms, a halogen atom, hydroxyl, nitro, cyano, amino, carboxyl, a C 2-8 acyl group, or an alkoxycarbonyl group comprising a C 1-8 alkoxy moiety; and
each of R 4 and R 5 independently is hydrogen, a C 1-8 alkyl group, or a C 1-8 alkyl group having one to three halogen atoms.

2. The method according to claim 1 , wherein R 1 is hydrogen.

3. The method according to claim 1 , wherein each of R 4 and R 5 is hydrogen.

4. The method according to claim 1 , wherein R 2 is a C 2-8 acylamino group having one to three halogen atoms.

5. The method according to claim 1 , wherein R 3 is hydrogen.

Assignees

• Univ Kyushu
• Nippon Chemiphar Co

Inventors

• Inoue Kazuhide
• Tsuda Makoto
• Matsumura Yuta

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• C07D313/12

  [b,e]-condensed · CPC title

• A61K31/5513 Primary

  1,4-Benzodiazepines, e.g. diazepam {or clozapine} · CPC title

• A61K31/495

  having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title